Rapid Micro Biosystems, Inc. (RPID)
Market Cap | 48.12M |
Revenue (ttm) | 20.56M |
Net Income (ttm) | -57.74M |
Shares Out | 37.09M |
EPS (ttm) | -1.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 53,853 |
Open | 1.10 |
Previous Close | 1.12 |
Day's Range | 1.04 - 1.15 |
52-Week Range | 0.83 - 1.89 |
Beta | 1.30 |
Analysts | Hold |
Price Target | 2.75 (+140.18%) |
Earnings Date | Nov 3, 2023 |
About RPID
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual micro... [Read more]
Financial Performance
In 2022, RPID's revenue was $17.13 million, a decrease of -26.25% compared to the previous year's $23.23 million. Losses were -$60.81 million, -22.08% less than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for RPID stock is "Hold" and the 12-month stock price forecast is $2.75.
News

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
LOWELL, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems Reports Third Quarter 2023 Financial Results
Reports third quarter 2023 total revenue of $6.1 million , representing growth of 30% compared to third quarter 2022

Rapid Micro Biosystems to Announce Third Quarter 2023 Financial Results on November 3, 2023
LOWELL, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solut...

Rapid Micro Biosystems to Exhibit at the 2023 PDA Pharmaceutical Microbiology Conference from October 2 – 4
LOWELL, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solu...

Rapid Micro Biosystems to Participate in the Virtual Gilmartin Group Emerging Growth Company Showcase
LOWELL, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solu...

Rapid Micro Biosystems to Participate in the Morgan Stanley 21st Annual Global HealthCare Conference
LOWELL, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solu...

Rapid Micro Biosystems Reports Second Quarter 2023 Financial Results
Reports second quarter 2023 total revenue of $5.0 million , representing growth of 30% compared to second quarter 2022

Rapid Micro Biosystems to Announce Second Quarter 2023 Financial Results on August 4, 2023
LOWELL, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solut...

Rapid Micro Biosystems Announces Appointment of Kirk Malloy, Ph.D. as Chair of its Board of Directors
LOWELL, Mass., July 18, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LOWELL, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation soluti...

Rapid Micro Biosystems Reports First Quarter 2023 Financial Results
Reports first quarter 2023 total revenue of $5.0 million , representing growth of 21% , compared to first quarter 2022

Rapid Micro Biosystems Announces the Appointment of Michael Wysocki as Senior Vice President, Sales and Marketing
LOWELL, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation soluti...

Rapid Micro Biosystems to Announce First Quarter 2023 Financial Results on May 5, 2023
LOWELL, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solu...

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Guidance
Reports fourth quarter 2022 commercial revenue of $4.4 million

Rapid Micro Biosystems to Participate in the Cowen 43rd Annual Health Care Conference
LOWELL, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2022 Financial Results on March 3, 2023
LOWELL, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue
Full year 2022 commercial revenue expected to be between $17.0 million and $17.2 million

Rapid Micro Biosystems to Present at 41st Annual J.P. Morgan Healthcare Conference
LOWELL, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems® Announces Publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology
LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solu...

Rapid Micro Biosystems Concludes Review of Strategic Alternatives
LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems Reports Third Quarter 2022 Financial Results
Reports third quarter 2022 commercial revenue of $4.7 million

Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System
LOWELL, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems to Exhibit at the 2022 PDA Pharmaceutical Microbiology Conference
LOWELL, Mass., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solut...

Rapid Micro Biosystems CEO Rob Spignesi to Speak at the 2022 PDA/FDA Joint Regulatory Conference
LOWELL, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solu...

Hill International, Rapid Micro Biosystems See Activist Investor Action
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.